Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2020-02-25 Board/Management Inform…
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Board/Management Information Classification · 95% confidence The document is titled 'MATERIAL CHANGE REPORT' and references Form 51-102F3, which is a Canadian regulatory form used for reporting material changes. The content details a material change involving receipt of a cannabis license and changes in board and management personnel. It includes specific dates and names of directors resigning and being appointed. The document is relatively short (3070 characters) and focuses on announcing these changes rather than providing detailed financial data or full reports. This fits the category of Board/Management Information (MANG), as it announces changes in the company's board of directors and senior management. It is not an annual report, audit report, or earnings release, nor is it a regulatory filing or report publication announcement. Therefore, the best classification is MANG with high confidence.
2020-02-25 English
News release - English.pdf
Regulatory Filings
2020-02-21 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Rapid Dose Therapeutics has secured government funding of $400,000 to support scale-up manufacturing and commercialization of a product. It focuses on the funding received, the purpose of the funding, and some company background. There are no financial statements, no detailed financial results, no regulatory form references, and no mention of shareholder votes or management changes. The document is short (4510 characters) and reads as a funding announcement rather than a detailed financial or regulatory report. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to company fundraising and financing activities.
2020-02-04 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ending November 30, 2019. The document is primarily an officer certification letter and does not contain actual financial data or substantive financial analysis. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself. The document length is under 5,000 characters and it is a certification, not the report itself.
2020-01-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the Interim CFO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended November 30, 2019. It is a Form 52-109FV2 Certification of Interim Filings for a venture issuer. The content is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing actual financial data or substantive financial analysis itself. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is short (3004 characters), and it is clearly a certification rather than the report or announcement of a report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-01-29 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis November 30, 2019' and contains detailed discussion and analysis of the financial condition and results of operations for the 9 months ended November 30, 2019. It includes forward-looking statements, revenue recognition policies, corporate developments, changes in key management personnel, capital transactions, research activities, and insurance matters. The document is substantive and contains financial data and management commentary, consistent with a Management Discussion and Analysis (MD&A) report. It is not a full annual report (10-K), nor is it a short earnings release or a simple announcement. The presence of detailed financial discussion and analysis for a period shorter than a full fiscal year (9 months) aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). 9M 2020
2020-01-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.